We would love to hear your thoughts about our site and services, please take our survey here.
From Wiki "According to Dealogic, Jefferies is the 7th largest investment bank in the world by revenue. Financial Times denotes Jefferies LLC as the fastest growing Investment Bank by global activity. Jefferies has a world renown position in Technology and Healthcare focused Investment Banking transactions "
Reply to the AIR was expected early May according to the March RNS, this later became 'May' and near the end of May was translated to 'imminent'. SP started to rise sharply mid April. It is now up around 60% since mid April. Perhaps some shareholders are satisfied with that profit and/or are less confident about the 'imminence' of the AIR reply so selling off.
The company RNS on 4th March sounded very confident of submitting a prompt reply to the AIR:
"Some of the technical information requested necessitates some targeted additional analytical studies. However, these additional analytical studies do not require patient samples and ANGLE anticipates that the necessary studies, which are already at an advanced planning stage, can be completed and the response submitted by early May."
The FDA process is on hold until Angle replies to the AIR which they received at the beginning of March (RNS on 4th March). They ha e 180 calendar days i.e. roughly end August to reply. If the reply is in time and satisfactorily deals with all points raised by the FDA then the process restarts. If not, the submission is considered to be withdrawn.
CW, Thanks for a very fair summary. Still holding but expectations have dropped. To be fair to Marsden he did say last November that successful vaccines would knock his 2021 & 2022 forecasts on the head and recently commented that they needed fires to put out. Reminds me of the old asthma results.
Henners, is Aurélien Mary's team using the Synairgen product? He published an article on Actu.fr on 7th March where he wrote that 3 teams were working on interferon - Bordeaux, his team in Amiens and the British spin-off, Synairgen. The Amiens project is a procedure they developed in house. 8 days administration instead of Synairgen's 14. You can find the Actu.fr article if you just Google Aurélien Mary and Synairgen. Well worth a read
Factions or Owl, do you know when he switched from Lambda to Beta? This is from his current web page --
The Jagannathan lab at Stanford University focuses on human immunology of infectious diseases.
The main focus of our group is studying naturally acquired immunity to malaria, novel interventions to prevent malaria in endemic settings, and the immunologic benefits of malaria control interventions.
Our group has also been drawn into the COVID-19 response.
Along with Dr. Upi Singh in the Division of Infectious Diseases and Geographic Medicine, Dr. Jagannathan is leading a trial of a novel therapeutic – Peginterferon Lambda (Lambda), a type III interferon - for the treatment of SARS-CoV-2 infected outpatients (NCT 04331899).
Dr. Jagannathan’s lab is also studying the impact of Lambda on the host immune response to SARS-CoV-2.
The Jagannathan lab at Stanford University focuses on human immunology of infectious diseases.
The main focus of our group is studying naturally acquired immunity to malaria, novel interventions to prevent malaria in endemic settings, and the immunologic benefits of malaria control interventions.
Our group has also been drawn into the COVID-19 response.
Along with Dr. Upi Singh in the Division of Infectious Diseases and Geographic Medicine, Dr. Jagannathan is leading a trial of a novel therapeutic – Peginterferon Lambda (Lambda), a type III interferon - for the treatment of SARS-CoV-2 infected outpatients (NCT 04331899).
Dr. Jagannathan’s lab is also studying the impact of Lambda on the host immune response to SARS-CoV-2.